Key result
The TNF-α -1031C and -863A alleles significantly increased the risk of upper gastrointestinal bleeding induced by enteric-coated aspirin in CHD patients (e.g., -1031 CC vs TT: OR 7.568; P=0.005).
Why the study?
The correlation between TNF-alpha polymorphisms and upper gastrointestinal bleeding induced by enteric-coated aspirin in patients with coronary heart disease was not established.
Do TNF-α polymorphisms increase the risk of upper gastrointestinal bleeding in CHD patients taking enteric-coated aspirin?
Case-Control (n=154)
Do TNF-α polymorphisms increase the risk of upper gastrointestinal bleeding in CHD patients taking enteric-coated aspirin?
TNF-α -863A and -1031C polymorphisms are associated with a significantly increased risk of upper gastrointestinal bleeding in CHD patients taking enteric-coated aspirin.
Answers are grounded in this paper and cite their sources.
No immediate change to aspirin use in CHD; leaves open whether TNF-α genotyping predicts UGIB risk.
OBJECTIVE: To investigate the correlation of tumor necrosis factor α (TNF-α) polymorphisms with upper gastrointestinal bleeding (UGIB) induced by enteric-coated aspirin in coronary heart disease (CHD) patients. METHODS: In total, 154 CHD patients taking enteric-coated aspirin were enrolled in this study. Patients were divided into the UGIB group (n = 57) and non-UGIB group (n = 97) based on the presence or absence of signs of UGIB, respectively. TNF-α polymorphism (-857C > T, -863C > A, and -1031T > C) genotyping was performed using polymerase chain reaction (PCR) amplification with sequence-specific primers (PCR-SSP). RESULTS: Patients who had the CC genotype and C allele of -1031T > C exhibited a significantly increase risk of UGIB after receiving enteric-coated aspirin (CC vs. TT: odds (OR) (95% confidence interval (CI)): 7.568 (1.527-37.49), P = 0.005; C vs. T: OR (95% CI): 1.852 (1.036-3.312), P = 0.036). Patients who had CA and CA + AA genotypes and the A allele of -863C > A also exhibited an increased risk of aspirin-induced UGIB (CA vs. CC: OR (95% CI): 2.415 (1.143-5.101), P = 0.019: CA + AA vs. CC: OR (95% CI): 2.218 (1.123-4.381), P = 0.021; A vs. C: OR (95% CI): 1.788 (1.039-3.078), P = 0.035). However, the TNF-α -857 C > T polymorphism was unrelated to the induction of UGIB by enteric-coated aspirin in CHD patients (P > 0.05). In addition, the haplotypes of CCC (-1031T > C, -863C > A, and -857C > T) markedly reduced the risk of aspirin-induced UGIB in CHD patients. CONCLUSION: TNF-α -863A and -1031C increased the risk of UGIB induction by enteric-coated aspirin in CHD patients, whereas TNF-α -857C > T was not correlated with the UGIB risk.
No takes yet. Share an insight, caveat, or question.
Tai‐ping Wang (2018) conducted a case-control in Coronary heart disease (n=154). TNF-α -1031T > C polymorphism (CC genotype) vs. TT genotype was evaluated on Upper gastrointestinal bleeding (UGIB) (OR 7.568, 95% CI 1.527-37.49, p=0.005). The TNF-α -1031C and -863A alleles significantly increased the risk of upper gastrointestinal bleeding induced by enteric-coated aspirin in CHD patients (e.g., -1031 CC vs TT: OR 7.568; P=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: